A Phase 3 interventional study of Dymista Nasal Spray and Fluticasone propionate nasal spray in Allergic Rhinitis, sponsored by Meda Pharmaceuticals. Completed at 41 sites in United States. Open to participants aged 4 Years to 11 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-31.
Sponsored by Meda Pharmaceuticals (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing fluticasone in Rhinitis, Allergic — none open to participants now, 1 under way, none of them phase 3. Fluticasone · Rhinitis, Allergic.
Among the 34 studies testing fluticasone in Rhinitis, Allergic, this one is the 8th largest by enrollment, is one of 2 that started in 2013, is one of 9 in phase 3, and was the 26th registered.
717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.
Browse Rhinitis, Allergic studies →None of the 34 studies testing fluticasone in Rhinitis, Allergic is open now. The open studies under Rhinitis, Allergic, anywhere →
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.
This study: 4 Years to 11 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 405 is above the median of 68 across 552 interventional studies indexed under Rhinitis, Allergic.
Median enrollment 63 across the 34 interventional studies. Of the 29 that completed or were terminated, 15 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Meda Pharmaceuticals, one of the names counted as Viatris Inc.. Under that name alone:
Meda Pharmaceuticals is the lead sponsor of 19 studies on the registry; none are open to participants now.
Viatris Inc. has 8 studies filed under Rhinitis, Allergic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing fluticasone in Rhinitis, Allergic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a 3 month safety study of Dymista Nasal spray in children aged 4 to 11 years with allergic rhinitis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
azelastine 137mcg per spray/fluticasone propionate 50mcg per spray one spray per nostril twice a day for three months
Drug: Dymista Nasal Spray
fluticasone propionate nasal spray 50mcg per spray per nostril twice a day
Drug: Fluticasone propionate nasal spray
Adverse Events Report
reports of treatment emergent adverse events
Time frame: 3 months of treatment
| Milestone | Dymista Nasal Spray | Fluticasone Propionate Nasal Spray |
|---|---|---|
| Started | 304 | 101 |
| Completed | 285 | 92 |
| Not completed | 19 | 9 |
reports of treatment emergent adverse events
| event | Dymista Nasal Spray | Fluticasone Nasal Spray |
|---|---|---|
| Adverse Events Report | 124 | 37 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dymista Nasal Spray | — | 1/304 (0.3%) | 114/304 (37.5%) |
| Fluticasone Propionate Nasal Spray | — | 0/101 (0%) | 25/101 (24.8%) |
| Event | Dymista Nasal Spray | Fluticasone Propionate Nasal Spray |
|---|---|---|
| gastroenteritis elevated LFTGastrointestinal disorders | 1/304 | 0/101 |
| Event | Dymista Nasal Spray | Fluticasone Propionate Nasal Spray |
|---|---|---|
| epistaxisRespiratory, thoracic and mediastinal disorders | 30/304 | 9/101 |
| headacheGeneral disorders | 20/304 | 3/101 |
| coughRespiratory, thoracic and mediastinal disorders | 11/304 | 3/101 |
| pyrexiaGeneral disorders | 10/304 | 2/101 |
| otitis mediaEar and labyrinth disorders | 9/304 | 3/101 |
| oropharyngeal painRespiratory, thoracic and mediastinal disorders | 9/304 | 0/101 |
| vomitingGastrointestinal disorders | 9/304 | 2/101 |
| abdominal pain upperGastrointestinal disorders | 8/304 | 2/101 |
| upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 8/304 | 1/101 |
| Age, Categorical(Participants) | Dymista Nasal Spray | Fluticasone Propionate Nasal Spray | Total |
|---|---|---|---|
| <=18 years | 304 | 101 | 405 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Dymista Nasal Spray | Fluticasone Propionate Nasal Spray | Total |
|---|---|---|---|
| Mean | 8.1 ± 2.07 | 8.1 ± 1.94 | 8.1 ± 1.9 |
| Sex: Female, Male(Participants) | Dymista Nasal Spray | Fluticasone Propionate Nasal Spray | Total |
|---|---|---|---|
| Female | 121 | 49 | 170 |
| Male | 183 | 52 | 235 |
| Region of Enrollment(participants) | Dymista Nasal Spray | Fluticasone Propionate Nasal Spray | Total |
|---|---|---|---|
| United States | 304 | 101 | 405 |
The record gives a start of Feb 2013 and a primary completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray · Fluticasone